Biology subjects

Menesson, E.

Publications and source records attributed to Menesson, E..

2 recordsLinked to original sources

bioRxiv2023

Effects of B lymphocytes In vitro Treatment with Rose Extract on Transmembrane Ligands

AimsThe study was performed to evaluate the role of red rose extract (Pierre de Ronsard) on B lymphocytes. Specifically the gene expression of CD20, CD30, CD40, and CCR5 in human B cells were studied after treatment with rose extract. MethodsRed rose extract was prepared at the dilution of 0.0075% (v/v) and stored until use at -20{degrees}C. Cell treatment was performed at 37{degrees}C on B cells. The cells were plated in 6 well plates at 1.5x106 cells per well and stored at -80{degrees}C. Total RNA extraction and quality control were performed. RTq-PCR was performed according to Genecopoeias instructions. The cycle threshold method ({Delta}{Delta}Ct) was used for data analysis. ResultsThe comparative Ct method quantification (2^-{Delta}Ct) and fold change for CD20, CD 30, CD 40 and CCR5 were - 5.65E+01, 4.80E-01, N/A, 2.47E-01; and 0.954,0.377, N/A and 0.577, respectively. The amount of total RNA extracted from about 4.5x106 cells was low and did not allow us to measure the RNA profile. The A260/A230 ratios were very low due to the low amount of RNA. The analysis of gene expression by qRT-PCR showed that CD40 was not expressed in untreated cells and cells treated with rose extract with the Ct values over 32. All other genes were expressed and well-measured in both B cell samples. ConclusionThe treatment with rose extract at 0.0075% (v/v) did not modify the expression of CD20. However, the expression of CD30 and CCR5 decreased with the rose extract treatment. The range of the fold change showed that the result of CD30 expression was more accurate than for CCR5.

molecular biology↗

bioRxiv2021

Rose Extract Treatment on the CD4+ T lymphocytes

Background and AimsTo study the effect of rose extract on CD4+T lymphocytes, and assess the cytokines response after cell treatment. In our previous study on endothelial cells, the rose extract reduced the secretion of inflammatory markers significantly. MethodsThe red rose extract used in this study was prepared and stored until use at -20{degrees}C. T cells were seeded in 96-well plates at 313500 cells/well in 100l of cell culture medium in duplicate, one half of the wells were used for biomarkers screening in the culture medium, and the other half for cytotoxicity assay. 24h after plating, the cells were treated in duplicate with 100l of red rose extract diluted at 0.5%, 0.1%, 0.05%, 0.01% and 0.005% (v/v) in cell culture medium or with culture medium only as control for 72h. Some other wells were for untreated cells, and cells treated with rose extract at 0.005% for 48h incubation time. After 48h and 72h, the corresponding wells were used for the cytotoxicity assay and from the duplicate wells, the cell culture media were collected and stored at -80{degrees}C until the biomarkers screening assay. ResultsCytotoxicity assay revealed insignificant changes. IFN-gamma, MCP-1, GRO, RANTES and TIMP, Angiopoietin 1 and MMP-9 were elevated. Except MMP-9 which had fold changes >2 other cytokines were minimally elevated at various concentrations and timing of rose extract treatment. None of the cytokines were less than 0.8-fold. ConclusionsUnlike in the endothelial cells, there is mild elevation in few inflammatory markers on T lymphocytes treatment by rose extract. Further studies need to be performed to estimate the clinical relevance.

cell biology↗